Abstract
Capecitabine is an oral pro-drug of the anti-cancer drug 5-fluorouracil (5-FU). The primary aim of this study was to develop a pharmacokinetic model for capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine (dFCR), 5'-deoxy-5-fluorouridine (dFUR), 5-FU and fluoro-β-alanine (FBAL), using data from a heterogeneous population of cancer patients (n=237) who participated in seven
... read more